New research identifies key subtype of bacterial vaginosis that increases chlamydia risk

The FDA on Fri­day ap­proved Neu­ro­crine Bio­sciences’ In­grez­za to treat adults with chorea as­so­ci­at­ed with Hunt­ing­ton’s dis­ease. In­grez­za, al­so known as val­be­nazine, was first ap­proved

GSK was found not li­able in the sec­ond ju­ry tri­al in­volv­ing the com­pa­ny’s heart­burn med­ica­tion, Zan­tac. The com­pa­ny said in a Sign up to read